AstraZeneca will delay the withdrawal of breast cancer drug Zoladex from the Australian market while it attempts to renegotiate a relisting on the Pharmaceutical Benefits Scheme following fierce patient backlash.
Under the new plan, Zoladex will remain on shelves until May 2027 but PBS prescriptions for the Zoladex 3.6mg monthly implant written by April 30 can still be filled until May 1, 2028.
Zoladex is a drug used by women with endometriosis or hormone receptor-positive metastatic breast cancer. It works by suppressing their sex hormones, which can drive the disease.
When AstraZeneca announced its intention to withdraw its 3.6mg dose from the Australian market for financial reasons, affected patients considered the move as a very real threat to their lives. Some were left so distressed that it was a major contributor to their decision to have their ovaries removed.
The withdrawal was due to happen in November. Not only would the drug be stripped from the PBS, it would be removed from sales entirely.
At the time, the government expressed its disappointment in the decision and said it had made “extensive and sustained efforts to retain the PBS listing” to no avail. Patient groups admonished both sides.
The dispute came amid growing concern that the PBS is not fit for purpose and needs considerable amendments or drug makers will overlook Australia as a favourable market. The drug’s supply has not been affected in similar international markets.
As anger grew, AstraZeneca announced a community access scheme would be rolled out to give patients with no alternative option ongoing access to the drug for free. However, patients and advocates said the pledge provided no guarantee of supply and could be reneged as easily as it was made.
The Australian can now reveal AstraZeneca and the government have been locked in closed-door negotiations to try to get Zoladex relisted on the PBS at a new price. However, the drug maker’s first application, made just weeks ago, was rejected.
“The Pharmaceutical Benefits Advisory Committee was unable to grant a price adjustment that would have allowed the continued PBS reimbursement of this medicine,” said Marie Guillet, country president, AstraZeneca Australia and New Zealand.
The Australian understands the company is highly likely to soon make a new application, which is why it has extended the drug’s supply by six months. AstraZeneca has consistently said its decision is based on financial pressure from multiple fronts.
“Zoladex monthly (3.6mg) has decades of clinical use in Australia and around the world,” Dr Guillet said. “It is, however, expensive to manufacture and the accumulation of years of inflation has increased the manufacturing cost, despite productivity improvements. On the other hand, the price is less than half what it was when first listed in 1991.
“Universal and equitable access to medicines is critical to the continued health of Australians. The PBS will require appropriate funding to ensure Australians are not denied access to medicines.”
The federal government last week announced it would make the drug Triptorelin, sold as Dishereline, available on the PBS from October for a range of conditions including breast cancer, endometriosis and uterine fibrosis. The drug is considered an alternative to Zoladex.
Health Minister Mark Butler said women should be able to access the medicines they need without barriers and that he would “continue to make sure women have access to affordable treatment, more choice and better care”.
Australians risk losing access to world’s best drugs, clinical trials
Mounjaro’s scathing rejection explains why drug access is failing
Why Xavier needs to go to the US for his cancer drugs
‘An afterthought’: Patients left waiting in drug price war
Patients ‘who could be cured’ are dying in NZ’s drug-funding crisis
‘Early menopause’: women risk drastic measures as cancer drug cut
Australia is not ready for the future of cancer care
‘Rationing system’ denies patients next-gen drugs
Australian lives on the line in global battle over drug pricing
Our PBS must evolve or risk being overwhelmed by costly new drugs
NZ’s in a free fall on medicines. Can we avoid the same fate?
Drug price disputes swamp medicine approvals committee
Multiple sclerosis drugs saved from PBS pricing axe
Kelly thought she was dying as ‘sinister’ Crohn’s disease flared
The medicines Australian patients are missing out on
Teacher pays $20k for cancer drug Australia won’t fund
Why you won’t be getting Wegovy on the PBS any time soon
‘Can hardly walk’, yet this doctor’s patients can’t get weight-loss drugs
Butler says weight-loss meds must be listed on the PBS
Keytruda now affordable to thousands more cancer patients
In Abby’s name: sister joins push for better access to medicines
A separate three-monthly Zoladex implant, for men with prostate cancer, remains unaffected by any of the changes to supply. However, the drug has now been approved for use for the management of oestrogen receptor-positive early and advanced breast cancer in pre- and perimenopausal women.
A decision is pending on whether the PBAC will recommend it for PBS listing for those conditions. With alternatives now available, AstraZeneca’s community access program to the 3.6mg Zoladex implant will not proceed.
Want to get healthy? Sign up to our free newsletter for trusted tips on diet, fitness, medical breakthroughs and guidance on sex and relationships here.